Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 162 recruiting now early-phase tilt #14 of 28,707 conditions

Colorectal Cancer: early-phase trial registry

162 of 394 indexed Colorectal Cancer trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #14 of 28,707 conditions by registered trial count.

394 US clinical trials · 162 currently recruiting · #14 of 28,707 conditions by registered trial count

Colorectal Cancer: 394 US clinical trials tracked, 162 recruiting.

Colorectal Cancer is the subject of 394 registered US clinical trials on ClinicalTrials.gov, 162 of them currently open to new participants. 13 are in Phase 3-4 (later-stage) and 201 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 22 of these trials.

Enrollment posture brief

Registry condition colorectal-cancer

OPEN 162 | RECR 41% | LATE 13 | EARLY 201 | RANK #14 | SPON 22

Nearest open-share peer: Erectile Dysfunction (41% recruiting · 34 trials)

Heart Failure41.1%Colorectal Cancer (this)41%Anxiety40.3%Pain28.1%Asthma18.5%
Open-enrollment share among volume-matched conditions near Colorectal Cancer

Colorectal Cancer lists 162 open slots (41% of 394 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Colorectal Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Colorectal Cancer is recruiting above its size-band peers.

    162 of 394 indexed trials (41.1%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Colorectal Cancer trials is spread across many organizations.

    Memorial Sloan Kettering Cancer Center accounts for 22 of 394 trials (5.6%). 222 distinct sponsors appear on at least one study for this condition label.

  3. Typical Colorectal Cancer enrolment sits around 132 participants.

    Median target enrolment is 132 among the 382 trials that report a genuine target (sentinel values excluded). 162 of those (42.4%) plan for fewer than 100 participants.

  4. Colorectal Cancer research is mostly interventional.

    323 interventional and 71 observational studies make up this index (82% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 1132Phase 269Phase 310Phase 43

Open and recent trials

394 total, page 8 of 8

COMPLETED 25 participants

Growth Factor Levels in the Blood of Patients Undergoing Radiation Therapy for Epithelial Cancer

Vanderbilt-Ingram Cancer Center

NCT00897793

COMPLETED Phase 2 24 participants

Skin Rash Study Before Chemotherapy in Colorectal & Head and Neck Cancer Patients

University of Louisville

NCT01874860

COMPLETED Phase 1 24 participants

Linaclotide Acetate in Preventing Colorectal Cancer in Healthy Volunteers

Mayo Clinic

NCT01950403

COMPLETED Phase 1 24 participants

Radiolabeled Monoclonal Antibody in Treating Patients With Advanced Colorectal Cancer

Memorial Sloan Kettering Cancer Center

NCT00003360

COMPLETED Phase 2 23 participants

Radiation Therapy and Chemotherapy Followed by Surgery and Combination Chemotherapy in Treating Patients With Rectal Cancer

Fox Chase Cancer Center

NCT00021398

COMPLETED NA 23 participants

Study Using Fluorine-18-Labeled Fluoro-Misonidazole Positron Emission Tomography to Detect Hypoxia in Locally Advanced (T3-T4 and./or N1)Primary Rectal Cancer Patients

Memorial Sloan Kettering Cancer Center

NCT00574353

COMPLETED Phase 2 22 participants

Phase II Trial of RAD001 in Refractory Colorectal Cancer

Swedish Medical Center

NCT00337545

COMPLETED Phase 1 22 participants

Lapatinib and Cetuximab in Patients With Solid Tumors

Georgetown University

NCT01184482

COMPLETED Phase 2 21 participants

Irinotecan in Treating Patients With Metastatic or Recurrent Colorectal Cancer

Case Comprehensive Cancer Center

NCT00002933

COMPLETED Phase 1 18 participants

Monoclonal Antibody Therapy Plus Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer

Memorial Sloan Kettering Cancer Center

NCT00003543

COMPLETED Phase 1 18 participants

A Study Comparing Oral Picoplatin With Intravenous Picoplatin in Subjects With Solid Tumors

Poniard Pharmaceuticals

NCT00465725

COMPLETED Phase 1 18 participants

Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia

Pfizer

NCT04803305

COMPLETED NA 17 participants

Lymphatic Mapping and Sentinel Lymph Node Biopsy in the Treatment of Colorectal Cancer

H. Lee Moffitt Cancer Center and Research Institute

NCT00005640

COMPLETED Phase 1 17 participants

Safety and Efficacy Study of BMS-908662 Alone or in Combination With Cetuximab in Subjects With K-RAS or B-RAF Mutation Positive Advanced or Metastatic Colorectal Cancer

Bristol-Myers Squibb

NCT01086267

COMPLETED Phase 1 16 participants

Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors

Masonic Cancer Center, University of Minnesota

NCT00703638

COMPLETED Phase 1 16 participants

Combination Chemotherapy and Oblimersen in Treating Patients With Advanced Colorectal Cancer

The University of Texas Health Science Center at San Antonio

NCT00055822

COMPLETED Phase 1 15 participants

Anti-CD3 x Anti-Erbitux® Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer)

Barbara Ann Karmanos Cancer Institute

NCT01420874

COMPLETED Phase 1 14 participants

Trial of Intraperitoneal (IP) Oxaliplatin in Combination With Intravenous FOLFIRI

University of Massachusetts, Worcester

NCT02833753

COMPLETED 14 participants

Collection of Blood Specimens for Circulating Tumor Cell Analysis

Viatar

NCT01943500

COMPLETED Phase 1 14 participants

Oxaliplatin With or Without Gefitinib in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer

University of Chicago

NCT00026299

COMPLETED Phase 2 13 participants

Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer

Case Comprehensive Cancer Center

NCT00005981

COMPLETED Phase 1 12 participants

Monoclonal Antibody Therapy in Treating Patients With Colorectal Cancer

Memorial Sloan Kettering Cancer Center

NCT00005616

COMPLETED NA 12 participants

Bovine Lactoferrin in Reducing Taste Disturbances in Patients With Colorectal Cancer Receiving Oxaliplatin-Based Chemotherapy

Wake Forest University Health Sciences

NCT01596634

COMPLETED Phase 2 11 participants

TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer

Yale University

NCT04166435

COMPLETED 10 participants

Trial of Cytoreductive Surgery and HIPEC in Patients With Primary and Secondary Peritoneal Cancers

Holy Name Medical Center

NCT03604653

COMPLETED 9 participants

The Patient-Perspective of Complications After Colon and Rectum Surgery: A Qualitative Analysis

Memorial Sloan Kettering Cancer Center

NCT02836535

COMPLETED 8 participants

Fludeoxyglucose F 18 PET Imaging in Determining Protein and Gene Expression Signatures in Patients With Premalignant Polyps or Colon Cancer

Memorial Sloan Kettering Cancer Center

NCT00550628

COMPLETED NA 5 participants

Colorectal Inflammatory Response to a Western-Style Diet

Rockefeller University

NCT00932308

COMPLETED NA 4 participants

TheraSphere® For Treatment of Metastases in Liver

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT04517643

COMPLETED Phase 1 2 participants

Irinotecan and Celecoxib in Treating Patients With Unresectable or Metastatic Colorectal Cancer

Roswell Park Cancer Institute

NCT00084721

COMPLETED Phase 1 1 participants

Escalating Doses of Oxaliplatin and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Children and Adolescents With Extensive Colon Carcinoma

M.D. Anderson Cancer Center

NCT02062749

COMPLETED Phase 1 1 participants

Immunoscintigraphy Using Radiolabeled Monoclonal Antibody in Finding Tumor Cells in Patients With Colorectal Cancer

City of Hope Medical Center

NCT00647153

COMPLETED Phase 2

Gefitinib in Treating Patients With Recurrent Metastatic Colorectal Cancer

Eastern Cooperative Oncology Group

NCT00025350

COMPLETED Phase 2

Oxaliplatin in Treating Patients With Recurrent Metastatic Colorectal Cancer

Prologue Research International

NCT00017082

COMPLETED Phase 1

Gene Therapy in Treating Patients With Colon Cancer That Has Spread to the Liver

Memorial Sloan Kettering Cancer Center

NCT00012155

COMPLETED NA

Oxaliplatin in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer

Roswell Park Cancer Institute

NCT00040820

COMPLETED Phase 2

Irinotecan in Treating Patients With Metastatic Colorectal Cancer

Memorial Sloan Kettering Cancer Center

NCT00003544

COMPLETED Phase 2

A Phase 2 Trial of ALIMTA (LY231514, Pemetrexed) Plus Oxaliplatin Administered Every 21 Days for First-Line Treatment of Patients With Advanced Colorectal Cancer.

Eli Lilly and Company

NCT00034619

COMPLETED NA

Regional Native American Community Networks Program (RNACNP)

Washington State University

NCT02843217

COMPLETED Phase 2

Isolated Hepatic Perfusion With Melphalan Followed by Combination Chemotherapy in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer

National Cancer Institute (NCI)

NCT00103298

COMPLETED Phase 3

Chemotherapy With or Without Isolated Hepatic Perfusion With Melphalan in Treating Patients With Colorectal Cancer That Has Spread to the Liver

National Institutes of Health Clinical Center (CC)

NCT00020501

COMPLETED Phase 2

Surgery With or Without Radiofrequency Ablation Followed by Irinotecan in Treating Patients With Colorectal Cancer That is Metastatic to the Liver

University of Washington

NCT00030563

COMPLETED Phase 1

Combination Chemotherapy With Suramin Plus Doxorubicin in Treating Patients With Advanced Solid Tumors

Mayo Clinic

NCT00003038

COMPLETED NA

Computerized Tomographic Colonography Compared With Standard Diagnostic Procedures in Detecting Colorectal Neoplasia

American College of Radiology Imaging Network

NCT00005809

← Previous Page 8 of 8

Phase Distribution

PhaseTrial count
Phase 1 132
Phase 2 69
Phase 3 10
Phase 4 3

Named interventions

Most-linked intervention names on Colorectal Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Cetuximab Drug
15 trials
Oxaliplatin Drug
14 trials
Bevacizumab Drug
11 trials
irinotecan hydrochloride Drug
9 trials
fluorouracil Drug
9 trials
Irinotecan Drug
9 trials
leucovorin calcium Drug
8 trials
Leucovorin Drug
7 trials

US sites by state

Facility locations filed on Colorectal Cancer trials. A trial with sites in several states counts in each.

California 133 trials
New York 100 trials
Texas 98 trials
Florida 86 trials
Massachusetts 64 trials
Pennsylvania 57 trials
Tennessee 53 trials
Michigan 51 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Colorectal Cancer page

394 registered trials, 162 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Colorectal Cancer condition card totals 394 registered trials; most-linked intervention Cetuximab; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.